• image

    the Phase 3 trial DIAGNODE-3

    and other ongoing trials

    Read More
  • image

    Developing precision therapies

    for type 1 diabetes

    VIDEO
  • image

    Intralymphatic immunotherapy

    with Diamyd®

    VIDEO

Press Releases 

Events & Mediawatch 

 September 4, 2025   Sweden

Events & Mediawatch 

 July 1, 2025   Sweden

Events & Mediawatch 

 June 25, 2025   Sweden

Events & Mediawatch 

 June 19, 2025   Sweden

Events & Mediawatch 

 June 4, 2025   Sweden

Company Presentation

 July 15, 2025
Download PDF

As we count down the months to the pivotal Phase 3 readout, our conviction grows stronger that Diamyd® may become the first precision immunotherapy approved for Type 1 Diabetes.

image Ulf Hannelius
President and CEO, Diamyd Medical AB
CEO Comments, Quarterly report 3, 24/25

Calendar

 Dates for financial information and other events
September 15 − September 19, 2025
EASD 61st Annual meeting
September 24, 2025
Biotech Hanse - BTH Forum
October 8, 2025
Year-end Report
Year-end Report 2024/2025
October 9, 2025
Leading Health Care - Konferens
October 25 − October 27, 2025
Breakthrough T1D Mission Summit
November 13, 2025
Annual Report
Annual Report 2025
December 4, 2025
Annual General Meeting
Annual General Meeting 2025

The Story of Diamyd Medical

The company founder Anders Essen-Möller reveals the story behind the company's founding and his mission to stop Type 1 Diabetes in its tracks. The film also features board member Karin Hehenberger, shedding light on the patient’s perspective, and board member Dr. Mark Atkinson speaking of the importance of the enzyme GAD in Type 1 Diabetes.

“ If it was not for the hundreds of clinical sites and their personnel, investigators, patients, investors, not to mention the fantastic entrepreneurial, yet diligent, Diamyd team - this current transformational precision therapy for autoimmune diabetes based on genetics, should probably still remain undiscovered.
How can I thank you all ? "

- Anders Essen-Möller, Chairman of the Board

Manufacturing of GAD65 in Umeå

Image
A facility for manufacturing of biological products is being set up in Umeå, the Capital of Västerbotten County in Sweden.
Read More

THE COMPANY

Diamyd Medical develops therapies for Type 1 Diabetes
The share is listed on Nasdaq First North Growth Market (ticker: DMYD B)


Read More

Order GAD for preclinical research

ORDER

Annual Report

  December 3, 2024
Annual Report cover image
Download

Contact Us

Diamyd Medical AB (publ)
Box 7349, SE-103 90 Stockholm
Visiting addresses:
Kungsgatan 29, SE-111 56 Stockholm
+46 8 661 00 26
Umeå:
Formvägen 7B, SE-906 21 Umeå

Subscribe

Follow Us

  ©
GAD PRODUCTS
Order GAD for preclinical research